© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
June 6th 2021, 5:00pm
Treatment with a novel combination therapy was associated with increased efficacy among patients with aggressive relapsed or refractory B-cell non-Hodgkin lymphoma and was also well tolerated.
January 14th 2021, 10:49pm
The Food and Drug Administration approved the supplemental new drug application for Xalkori (crizotinib) to treat children and young adults between the ages of 1 and 21 with relapsed or refractory, systemic ALK-positive anaplastic large cell lymphoma.
January 6th 2021, 10:00pm
The FDA has not yet reached a decision on an application for the approval of a CAR-T cell therapy product for the treatment of relapsed/refractory large b-cell lymphoma and, according to Bristol Myers Squibb, a new action date for the decision has not been set.
December 18th 2020, 4:30pm
From a new study showing data that patients with cancer, especially Black patients with cancer, are at a higher risk for COVID-19 than non-cancer patients to NFL punter Rigoberto Sanchez making a speedy recovery after surgery for cancer, here’s what’s happening in the cancer space this week.
December 17th 2020, 10:52pm
For multiple patients with blood cancers who would normally use Rituxan, the Food and Drug Administration has approved the biosimilar Riabni based off highly similar clinical evidence between the two drugs, potentially lowering costs for patients.
December 17th 2020, 4:00pm
In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Asher Chanan-Khan about current standards of care for Waldenstrom macroglobulinemia, as well as a clinical trial looking at a novel therapy.
December 8th 2020, 2:15pm
In an interview with CURE®, a Waldenstrom’s macroglobulinemia expert discusses the long-term benefits of the targeted combination of Imbruvica and Rituxan.
December 6th 2020, 7:30pm
The benefit observed in patients with Waldenstrom’s macroglobulinemia treated with Imbruvica (ibrutinib) plus Rituxan (rituximab), compared with placebo and Rituxan, focused on survival and response to the treatment, both of which occurred despite prior treatment and genotypes.
December 2nd 2020, 7:00pm
Safety and efficacy observed in this real-world study for patients with non-Hodgkin lymphoma similarly reflect findings from previous pivotal trials.
December 2nd 2020, 4:00pm
A novel type of immunotherapy known as chimeric antigen receptor, or CAR, T cell therapy is a hot topic in the news and in the lab. But what does this treatment consist of, and how was it developed?
Novel Drug Induces Robust Responses in von-Hippel Lindau Disease-Associated Kidney Cancer
The Guide’s Silhouette
The Journey to Personalized Cancer Vaccines
Preventative Kineret May Ease CAR T-Cell Therapy Side Effects in Multiple Myeloma